RxDoctor Payments Data

Greer Noonburg, MD

Orthopaedic Surgery · Savannah, GANPI 1417999889

Payments from drug & device makers

$454in general payments, 2019–2025

Across 13 payments — averaging $34.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vericel Corporation$198
  • Tenex Health Inc.$65
  • Amgen$61
  • Medacta USA, Inc.$32
  • Johnson & Johnson$22
  • Boston Scientific$17
  • plus $59 from 4 others

What the payments were for

  • Food & beverage$454100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Vericel Corporation1$198
Tenex Health Inc.1$65
Amgen(2 entities)3$61
Medacta USA, Inc.2$32
Johnson & Johnson1$22
Boston Scientific1$17
Stryker1$16
Zimmer Biomet1$16
Pacira Therapeutics, Inc.1$16
Smith+Nephew1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$454 in reported general payments places this provider in the 20th percentile of 654 orthopaedic surgery providers in Georgia.

See all orthopaedic surgery providers in Georgia

Medicare billing

Part B allowed, 2024
$235,895
Medicare patients
358
Services billed
4,901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban15$6,145
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen135$1,028
Cephalexin51$779
Celecoxib14$304
Tramadol Hcl68$269
Promethazine Hcl39$256
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$198
Acetaminophen-CodeineAcetaminophen With Codeine26$183
Meloxicam52$149
Hydromorphone Hcl22$144
Cyclobenzaprine Hcl13$61
Methylprednisolone13$60

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$22$6,14515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 654 orthopaedic surgery providers in Georgia.

Other orthopaedic surgery in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →